Skip to Content

Gemini Therapeutics Inc Ordinary Shares GMTX Stock Quote

| Rating as of

Morningstar‘s Stock Analysis GMTX

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics GMTX

Company Profile GMTX

Business Description

Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health. Variations in the gene that encodes CFH strongly correlate with an increased risk of developing AMD.

Contact
300 One Kendall Square, 3rd Floor
Cambridge, MA, 02139
T +1 617 401-4400
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 5